Somewhat Positive News Coverage Somewhat Unlikely to Impact Foundation Medicine (FMI) Stock Price

Press coverage about Foundation Medicine (NASDAQ:FMI) has been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Foundation Medicine earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.339789112557 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:

Shares of Foundation Medicine (NASDAQ FMI) opened at $65.60 on Thursday. Foundation Medicine has a 52 week low of $22.40 and a 52 week high of $75.20. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.03 and a current ratio of 2.24. The company has a market cap of $2,380.00, a P/E ratio of -14.68 and a beta of -0.03.

Several analysts have recently commented on the stock. Zacks Investment Research raised shares of Foundation Medicine from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a research note on Monday, November 6th. BidaskClub raised shares of Foundation Medicine from a “hold” rating to a “buy” rating in a research note on Tuesday, December 12th. Finally, Goldman Sachs Group assumed coverage on shares of Foundation Medicine in a research note on Monday, January 29th. They set a “neutral” rating and a $73.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Foundation Medicine has an average rating of “Hold” and an average target price of $52.25.

In related news, CFO Jason Ryan sold 21,726 shares of the stock in a transaction that occurred on Tuesday, December 5th. The shares were sold at an average price of $61.26, for a total value of $1,330,934.76. Following the transaction, the chief financial officer now directly owns 55,639 shares in the company, valued at $3,408,445.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Troy Cox sold 26,713 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $70.13, for a total transaction of $1,873,382.69. Following the completion of the transaction, the chief executive officer now owns 224,345 shares in the company, valued at $15,733,314.85. The disclosure for this sale can be found here. Insiders sold 228,717 shares of company stock worth $14,987,592 over the last 90 days. 2.70% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Foundation Medicine (FMI) Stock Price” was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://weekherald.com/2018/02/15/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-foundation-medicine-fmi-stock-price.html.

About Foundation Medicine

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply